Adc Therapeutics SA (NYSE: ADCT) is 76.38% higher on its value in year-to-date trading and has touched a low of $1.05 and a high of $4.13 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADCT stock was last observed hovering at around $3.09 in the last trading session, with the day’s gains setting it 0.42%.
Currently trading at $3.51, the stock is 74.54% and 118.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.69 million and changing 13.59% at the moment leaves the stock 60.60% off its SMA200. ADCT registered 5.41% gain for a year compared to 6-month loss of 58.11%. The firm has a 50-day simple moving average (SMA 50) of $1.5722 and a 200-day simple moving average (SMA200) of $2.18225.
The stock witnessed a 145.45% gain in the last 1 month and extending the period to 3 months gives it a 120.75%, and is 44.44% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.99% over the week and 10.45% over the month.
Adc Therapeutics SA (ADCT) has around 265 employees, a market worth around $348.11M and $75.82M in sales. Profit margin for the company is -197.64%. Distance from 52-week low is 234.29% and -15.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-71.25%).
with sales reaching $17.82M over the same period.The EPS is expected to grow by 1.44% this year, but quarterly earnings will post 9.41% year-over-year. Quarterly sales are estimated to grow 2.37% in year-over-year returns.
Adc Therapeutics SA (ADCT) Top Institutional Holders
113.0 institutions hold shares in Adc Therapeutics SA (ADCT), with institutional investors hold 75.88% of the company’s shares. The shares outstanding are 99.18M, and float is at 77.91M with Short Float at 5.56%. Institutions hold 59.67% of the Float.
The top institutional shareholder in the company is REDMILE GROUP, LLC with over 15.27 million shares valued at $48.25 million. The investor’s holdings represent 15.9568% of the ADCT Shares outstanding. As of 2024-06-30, the second largest holder is PROSIGHT MANAGEMENT, LP with 9.57 million shares valued at $30.24 million to account for 10.0009 of the shares outstanding. The other top investors are ORBIMED ADVISORS LLC which holds 4.32 million shares representing 4.5112% and valued at over $13.64 million, while BLACKROCK INC. holds 3.7148 of the shares totaling 3.55 million with a market value of $11.23 million.
Adc Therapeutics SA (ADCT) Insider Activity
The most recent transaction is an insider purchase by Redmile Group, LLC, the company’s 10% Owner. SEC filings show that Redmile Group, LLC bought 100,000 shares of the company’s common stock on Dec 11 ’24 at a price of $3.04 per share for a total of $0.3 million. Following the purchase, the insider now owns 15.67 million shares.
Adc Therapeutics SA disclosed in a document filed with the SEC on Dec 11 ’24 that Redmile Group, LLC (10% Owner) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Dec 11 ’24 and was made at $3.04 per share for $0.3 million. Following the transaction, the insider now directly holds 13.15 million shares of the ADCT stock.
Still, SEC filings show that on Dec 04 ’24, Redmile Group, LLC (10% Owner) disposed off 25,352 shares at an average price of $2.07 for $52479.0. The insider now directly holds 15,566,731 shares of Adc Therapeutics SA (ADCT).
